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The chronic leukemias—chronic granulocytic
leukemia (CGL), chronic lymphocytic leukemia (CLL),
and hairy cell leukemia (HCL)—are uncommon diseases
characterized by a chronic course and by organ infiltra-
tion and bone marrow replacement. Recently our under-
standing of the pathophysiology of these diseases has
improved. Treatment results in symptomatic improve-
ment, although little has been gained in terms of in-
creased survival in these patients.
Chronic Granulocytic Leukemia
Chronic granulocytic leukemia (CGL) has been shown
to be a disorder of the hematopoietic stem cell.
Cytogenetic and enzymatic evidence has shown CGL to
arise from a single clone of cells.'-^ In over 90% of cases,
it is associated with an acquired chromosomal abnor-
mality, the Philadelphia chromosome (Ph'). The major
clinical manifestations are due to overgrowth of
granulocytes in the marrow and elsewhere in the re-
ticuloendothelial system. Most cases can be controlled
with a variety of agents for two to four years, but 75%-
80% ofthe patients die with an acute terminal phase of
their illness, variously called accelerated phase, blast
phase, or metamorphosis of CGL.
Clinical Features
CGL accounts for 20% of adult leukemias in the
United States (3500 cases/yr).^ Its peak incidence is at
age 40, range 25-60. Proposed etiologic factors include
ionizing radiation and certain chemicals and viruses.
The onset is usually insidious, with the history being one
of evolution of worsening signs and constitutional
symptoms over two to six months. At presentation, the
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patient may have fatigue, decreased exercise tolerance,
night sweats, and weight loss. Fever is uncommon at
presentation. Bone pain or a sense of fullness in the
upper abdomen due to splenic enlargement may occur
as the disease progresses. Bleeding manifestations may
occur due to abnormalities of platelet number (too many
or too few), or abnormalities of platelet function. Gener-
ally, at presentation, symptoms are mild and the pa-
tient's overall status is good.
Laboratory and Cytogenetic Features
Peripheral blood and bone marrow examination in the
chronic phase of CGL reveal characteristic abnor-
malities. Normal appearing granulocytes in all stages of
development are present in the peripheral blood with a
mean leukocyte count at presentation over 100,000/
mm.3 The mean hemoglobin is 10 gm%, and platelet
count in the normal or elevated range sometimes ex-
ceeds one million at diagnosis. In the chronic phase,
promyelocytes and myeloblasts do not exceed 10-15%
of the total cell population in the peripheral blood or
bone marrow. Bone marrow aspirates from any site are
hypercellular with marked granulocytic hyperplasia.
Leukocyte alkaline phosphatase (LAP) is a neutrophil
enzyme whose precise function and subcellular locali-
zation remain unclear.* LAP activity is characteristically
absent or markedly reduced in patients with uncompli-
cated CGL in chronic phase. Elevation of LAP is often
seen at metamorphosis. The pathophysiology of low LAP
scores in chronic phase CGL remains unclear.
CGL is the only human malignancy with a specific
chromosomal abnormality, the (Ph") chromosome.^
Since its initial description in 1960 by Nowell and
Hungerford,^ the Ph' chromosome has been shown to be
present in the bone marrow of 85-90% of all patients
with CGL. In most cases, the Ph' chromosome is com-
posed of deleted chromosomal material from chromo-
some 22 which had been translocated onto one of the
no 9 chromosomes.
In patients with leukocytosis and a hypercellular mar-
row, detection of the Ph> chromosome is diagnostic of
CGL. The detection of Ph' chromosome in an
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asymptomatic individual has been described as a marker
for development of the disease at a later time.'' Sporadic
cases of acute granulocytic leukemia bearing the Ph'
chromosome have been reported, but may represent
CGL presenting in blast phase without a clinically appa-
rent chronic phase. The Ph' chromosome persists
throughout the course of the disease. The appearance of
multiple Ph' chromosomes, or additional chromosomal
anomalies may precede, or accompany metamorphosis
in CGL.̂  The functional significance of the Ph' chromo-
some is unknown.
Metamorphosis of CGL
Despite effective therapy for the symptoms and signs
of chronic phase CGL, 75-80% of patients develop a
more acute phase of their disease which is refractory to
therapy.^ This transformation may be sudden, resulting
in the death of the patient in a period of weeks, or it may
have a more chronic course with resulting death in a
period of months, or a year or longer. This change in
disease behavior, termed metamorphosis, accelerated
phase, or blast crisis, occurs most commonly 2y2 to 3
years after diagnosis. As time from diagnosis increases,
the risk of metamorphosis increases. Symptoms of
metamorphosis frequently resemble symptoms at pres-
entation of disease, but may also include drenching
night sweats, bone pain due to lytic bone lesions,' myal-
gias, and arthralgias and signs of meningeal involve-
ment. Lymphadenopathy and recurrent infection, un-
common in the chronic phase, may become prominent
in metamorphosis. The symptoms, physical signs, and
hematologic picture of metamorphosis of CGL may be
out of step with one another.'"-" Laboratory findings
include increased numbers of circulating blasts and
progranulocytes in some cases and severe pancytopenia
in others. The LAP score may rise to normal levels. Nee-
dle aspiration of marrow yields variable results: a left
shift in granulopoiesis is more prominent in this phase,
but occasionally a normal aspirate may be obtained.
Therapy and Prognosis
Multiple agents are available that control signs and
symptoms of chronic phase CGL. Although busulfan re-
mains the most widely used chemotherapeutic agent in
CGL,'^ enthusiasm for its use has waned due to its
pulmonary toxicity and cases of severe myelosuppres-
sion related to its use. Hydroxyurea may be effective in
chronic phase or in early metamorphosis and is espe-
cially useful in cases where rapid reduction in white cell
count is necessary. Myelosuppression due to hy-
droxyurea is rapidly reversible upon discontinuation of
therapy, a feature not seen with busulfan. None of these
agents, however, have altered the natural history of CGL.
Radiation therapy, once popular in this disease, is cur-
rently reserved for palliative treatment of symptomatic
splenomegaly, or control of extramedullary tumors
composed of granulocytic precursors, so called
"chloromas." The median survival of patients in most
series is approximately 3-3V2 years; but varies widely.
Most patients who develop an accelerated phase die due
to infection or because of bleeding.'^ No cures of CGL
by chemotherapy or radiation therapy have been
reported.
Therapy of metamorphosis in CGL has been extremely
disappointing. Because the clinical and hematologic
manifestations of this phase of the disease are variable,
new forms of therapy have been difficult to evaluate.
Since metamorphosis has been so refractory to current
therapeutic efforts, recent attempts at eradication of
CGL in the chronic phase, before the emergence of a
refractory disease state, have been made. These have
included intensive combination chemotherapy,'"" elec-
tive splenectomy in the chronic phase, leukapheresis,
immunotherapy, and, in a few cases, autologous marrow
infusion or allogeneic bone marrow transplant.'^''^ All of
these approaches must presently be regarded as
investigational.
These therapeutic maneuvers are being made to
change the course of disease, and thereby the survival of
patients with CGL. Of the current methods being tried,
autologous marrow infusion or bone marrow transplan-
tation while in chronic phase following high dose
chemotherapy, may offer the most promise. It is too early
yet to say whether or not intensive chemotherapy given
in the chronic phase of the disease will change its
course.
Chronic Lymphocytic Leukemia
A disease of unknown etiology, CLL is the most com-
mon leukemia seen in the Western countries. Its course
is variable but in general is characterized by gradual
accumulation of mature appearing lymphocytes in mar-
row and RES. Eventual involvement of other organ sys-
tems occurs, ie, skin, liver, lung, and Gl tract. These
well-differentiated lymphocytes are now well charac-
terized as abnormal, immunologically inert B cells in the
majority of cases, although T cell variants have been
described."^ Major advances in our understanding of the
pathogenesis of CLL have occurred recently, but have
not been accompanied by major therapeutic advances.
Median survival in most series is in the range of five
years. Recently, staging systems for CLL have been in-
troduced which should help evaluate efficacy of therapy
in comparable groups of patients.
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Clinical Features
The presentitig features in CLL vary widely. Twenty-
five to 30% of patients are asymptomatic at diagnosis.
Other patients may develop signs and symptoms of
anemia, or they may discover an enlarged lymph node
which leads to diagnosis. Less common presentations
include bleeding due to thrombocytopenia, skin infiltra-
tion or erythroderm, bony pain, or symptomatic
splenomegaly.
The physical examination is most striking for
generalized lymphadenopathy. Hepatosplenomegaly is
frequently present, but marked hepatosplenomegaly is
rarely a presenting feature without lymphadenopathy.
Infectious complications of CLL may bring the patient to
medical attention. Fever is nearly always due to infec-
tion rather than to the disease itself. Persistant fever
should suggest infection; rarely it may indicate
emergence of another lymphoproliferative process such
as diffuse histiocytic lymphoma ("Richter's syndrome"),
which may coexist with CLL. Bacterial infections are
common; fungal infections and infections with
pneumocystis and other opportunists may be seen in
patients treated with corticosteroids.
At presentation, the lymphocyte count varies from
5,000/mm^ on upwards, and counts greater than
100,000/mm^ are not unusual. Mild to moderate anemia
is present at diagnosis in up to 50% of patients. Anemia
is usually normochromic and normocytic; the Coomb's
test is positive in one-third of cases. Mild throm-
bocytopenia is common at diagnosis. Five percent of
patients have a detectable monoclonal paraprotein on
protein electrophoresis. In other patients depressed
serum globuMn levels may be present. In advanced CLL,
factors which may complicate decreased host defenses
and low serum globulins include malnutrition, protein
losing enteropathy, or chemotherapy. Variable defects in
cellular immunity have been described that may con-
tribute to a tendency toward infection, especially infec-
tion of skin, respiratory tract, and genitourinary tract.
Variability in clinical features and course in CLL have
made analysis of survival data difficult until recently. Rai
et al have introduced a clinical staging system useful in
assessing prognosis.'* According to their system, the du-
ration of survival for patients with CLL is related in-
versely to "stage" of disease (Table 1). Such "staging
systems" may allow stratification of patients for more
accurate comparisons of effects of treatment on survival.
Other prognostic indicators are currently being
evaluated.
Most cases of CLL are B-cell disorders as defined by
membrane receptors on the malignant cells, but recently
several reports have appeared in the literature describing
patients whose proliferating cells are T cells.'^ Some of
these latter patients have had unusual clinical pres-
entations, characterized by massive splenomegaly with-
out lymphadenopathy, and prominent neutropenia, and
in many cases by skin involvement. It is as yet unclear
whether T-cell CLL carries a different prognosis than
B-cell CLL.
Therapy and Prognosis in CLL
It remains unclear whether or not antileukemic
therapy in CLL changes survival. Indications for initiating
therapy vary, and many patients are observed from
months to years after diagnosis before they begin treat-
ment. Since no form of therapy has unequivocally been
shown to alter the prognosis in CLL, the goal of treatment
is palliation of symptoms and signs of disease activity.
Unlike in CCL, where an acute phase occurs in the
majority of cases, acute termination is very rare in CLL.
Radiotherapy may be useful in occasional patients with
large lymph node masses and painful splenomegaly, al-
though chemotherapy is useful in these settings as well.
Systemic benefit from splenic or thymic irradiation or
total body irradiation has been reported, but these
modes of therapy rennain controvei'sial.
Alkylating agent therapy with or without cortico-
steroids remains the most widely used treatment for pa-
tients with CLL who require treatment. Chlorambucil
given daily on a sliding scale or in higher doses
biweekly, has been an effective and well-tolerated
agent. Cyclophosphamide and melphalan appear to be
TABLE 1.









Absolute lymphocytosis plus lymphadenopathy
Absolute lymphocytosis and lymphadenopathy, plus
enlarged liver and/or spleen
Absolute lymphocytosis and lymphadenopathy, plus
anemia (hemoglobin > n g/dl)
Absolute lymphocytosis and lymphadenopathy, plus
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as effective as chlorambucil. In most series 70% or more
of patients will improve in terms of general sense of
well-being, decrease in lymphadenopathy and
splenomegaly, decrease in lymphocyte count, and. in
about 50% of patients, increase in hematocrit. Cortico-
steroids. in doses of 15-50 mg/day of prednisone. are
effective as a temporary measure to reduce many of the
symptoms and signs of CLL. but side effects of long-term
steroids are numerous. Complete remissions (complete
disappearance of signs and symptoms of disease) with
single agents or corticosteroids are rare. Combination
chemotherapy.^''" effective in lymphomas and
myelomas, has been tried in CLL with some promising
results, but all of these studies are small and use histori-
cal controls. Controlled, randomized studies are needed.
The incidence of second malignancies in CLL is dif-
ficult to estimate but most authors agree-that it has in-
creased. In some series, the incidence is up to 15-20%
(including skin cancer). Unlike in Hodgkin's disease or
myeloma, there appears to be no clear-cut relationship
between therapy and emergence of second malignancy
in CLL.
Although our understanding of the pathophysiology of
CLL has improved, therapeutic advances have been
slow. Combination chemotherapy may achieve com-
plete responses, however, at present the overall effect of
complete remission on duration of survival cannot be
assessed. Careful randomized studies using concurrent
controls must be done utilizing clinical staging of pa-
tients. The place of other therapeutic modalities, such as
total body irradiation, organ irradiation, or extracor-
poreal irradiation remains unclear.
Hairy Cell Leukemia
Bouroncleetal^^ described another chronic leukemia,
hairy cell leukemia (HCL) or leukemic reticuloen-
dotheliosis. Unlike in CGL and in CLL where
leukocytosis is the rule. HCL patients frequently present
with pancytopenia. The importance of distinguishing
HCL from the other chronic leukemias and from the
lymphoproliferative disorders lies in the fact that most
patients with HCL have shown little response to the
usual therapeutic maneuvers for these disorders. There-
fore, efforts have been directed toward more precisely
characterizing the "hairy cell" and the clinical presenta-
tion and course of this disease.
Clinical Manifestations
Bouroncle described clinical findings in 82 patients,
which she followed for up to 20 years.̂ ^ Her series of
patients with HCL comprised only 2% of all leukemias
seen in a tertiary referral hospital. Men predominate in
ratios of between 4: and 7:1 in most series. Onset of the
disease is usually in the sixth decade, but cases have
been described ranging from age 20-70.
The onset of HCL is insidious with malaise, fatigue,
and abdominal fullness due to splenomegaly being the
most common complaints. Other presenting symptoms
include bleeding in 15-30%. symptoms related to mas-
sive splenomegaly in 15%, and infection 15%. Fever,
chills, and extreme weight loss are uncommon at diag-
nosis. Occasionally the diagnosis of HCL may be made
as an incidental finding on routine hemogram.
Massive splenomegaly is the most characteristic sign
at diagnosis. Hepatomegaly is present at diagnosis in
20-50% of patients in various series, but lym-
phadenopathy is unusual. Skin lesions due to HCL are
uncommon, encountered in 10% of cases, which helps
to separate HCL from Sezary syndrome and T cell lym-
phoma also characterized by abnormal appearing circu-
lating mononuclear cells.
Lahoratory Findings
Routine laboratory values except for the hemogram
are nonspecific. In contrast to CLL. serum protein ab-
normalities are rare. Most patients present with pan-
cytopenia. Mild to moderate normochromic. normocytic
anemia is common. Hemolytic anemia may occur due
to hypersplenism and is usually Coomb's negative.
Leukopenia and thrombocytopenia are frequently more
pronounced than anemia. At presentation. 50-60% of
patients have white counts <3000/mm''. White blood
counts exceeding SO.OOO/mm''' are unusual except after
splenectomy. The percent of circulating hairy cells var-
ies widely. Absolute granulocytopenia and mono-
cytopenia are exceedingly frequent findings. At diag-
nosis, half of the patients have thrombocytopenia with
platelet counts <100.000/mm\ The diagnosis of HCL is
confirmed by finding the characteristic mononuclear
"hairy" cell with its multiple cytoplasmic projections in
peripheral blood and bone marrow smears. Phase con-
trast microscopy of hairy cells, which may demonstrate
the distinctive slender hair-like projections, has been
very helpful in diagnosis. Electron microscopy may also
be helpful. The bone marrow is virtually always involved
in hairy cell leukemia. Attempts at bone marrow aspira-
tion are unsuccessful ("dry tap") in up to 50% of cases.
The use of the cytochemical acid phosphatase stain
has been helpful in the diagnosis of HCL. In 90% of
cases, hairy cells contain the tartrate resistent isoenzyme
of acid phosphatase (TRAP) in their cytoplasm.̂ "* Al-
though characteristic of HCL. TRAP, is not specific. It has
been reported as uncommon in CLL. infectious
mononucleosis. lymphoblastic lymphoma and rare in
"reactive lymphocytosis." but the intensity of the stain-
ing in all of these cases is less than that seen in hairy cell
leukemia.
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Clinical Course
HCL is a chronic disease with a variable course. Some
patients succumb early to infection, and other may sur-
vive over 20 years. In general, the course is one of slow
progression over months to years with progressive organ
and marrow infiltration with hairy cells eventually lead-
ing to organ failure. The majority of patients are able to
live relatively normal lives until late in their course. In-
fections, particularly pneumonia and septicemia due to
gram negative organisms and staphylococcus are com-
mon during the course of the disease.̂ ^ Tuberculosis and
infection with atypical mycobacteria have been reported,
as have fungal pneumonias. Pneumocystis is uncommon
except in patients treated with steroids. In most pub-
lished series, infection is the cause of death in one-half
to three-quarters of patients. Because the infectious
complications in HCL are so frequent and so severe, as a
rule it is assumed that any fever in these patients is due to
infection.
The origin of neoplastic cells in HCL remains contro-
versial. Morphologic appearance alone suggests origina-
tion from monocytes or lymphocytes. Surface marker
and functional studies have not been conclusive and it
has variously been suggested that the cell of origin for
the "hairy cell" is a lymphocyte, a monocyte, or a hy-
brid cell. The cell from which the "hairy cell" originates,
and the factors determining the direction of its differ-
entiation are unknown. No variation in clinical course or
survival has been demonstrated for any particular cellu-
lar characteristic demonstrated by the malignant cell.
Therapy
Therapy in HCL has been difficult to evaluate because
of the variability of the disease, and no controlled studies
are available. As a result, treatment remains uncertain.
Splenectomy remains the mainstay of therapy, with most
investigators in agreement that splenectomy is appropri-
ate when complications due to pancytopenia become a
management problem. The surgical morbidity and mor-
tality is acceptable but great care must be taken to avoid
infection. In cases where splenectomy or pancytopenia
is asymptomatic, the value of early splenectomy is de-
bated. In most series, 75-90% of patients undergoing
splenectomy show improvement in hemogram, usually
within the first few weeks postsplenectomy.
Many of the patients who initially respond to splenec-
tomy require additional therapy after varying periods of
time. Recent series stress the poor results obtained with
either corticosteroid therapy or cytotoxic therapy, espe-
cially when they are given prior to splenectomy.
Clinical experience with combination chemotherapy
in HCL is limited. Sporadic responses to aggressive
combination chemotherapy for splenectomy failures
have been reported. The results of leukaphoresis in one
remarkable case have recently been described by Fay et
al.^* Golomb^' has suggested what is currently the pre-
vailing approach: (1) observe the rate of progression of
disease and the degree of pancytopenia; (2) recurrent
infections due to neutropenia, refractory anemia, or
thrombocytopenia may necessitate treatment with
splenectomy as the initial therapy; (3) if response to
splenectomy is poor or the patient relapses after an ini-
tial response, chemotherapy may be indicated; and (4)
other therapeutic interventions may show promise bul: at
present are investigational (leukaphoresis, monocyte in-
fusions). Definitive recommendations for therapy await
further delineation of the specific nature of the disease
and cooperative studies of treatment.
Conclusion
In summary, the chronic leukemias are relatively un-
common malignancies of variable course. Etiology and
pathogenesis remain obscure. Although clinical remis-
sions can be obtained, a definite impact of treatment on
survival has not been clearly demonstrated. Trials of
more aggressive therapy in all the chronic leukemias,
including autologous and allogeneic bone marrow infu-
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On Fleas
On the basis of attachment to hosts, Harwood and James (1979) segregated fleas into 4 groups. C.
can/5 belongs to that group of fleas that easily leave their hosts and may transfer to other hosts of the
same or a different species. A massive build-up of flea population probably occurred in the soil under
plant cover around the house prior to their movement into the house. In a humid climate (such as
Nigeria's) immature stages and adult fleas may be quite abundant outdoors and around homes. This
inordinate rise in flea population is made possible because in C. canis there is no reproductive
synchronisation with host factors as occurs for the rabbit flea, Spilopsyllus cuniculi which undergoes
ovarian maturation only on pregnant dogs or in response to corticosteroids. This also explains the
observation of a massive build-up of C. canis in a disused sheep house about 12 months after the
sheep had been removed.
One consequence of this human infestation was severe itching which followed the flea bites. There
was development of indurated popules and skin rashes. Generally, there was anxiety, restlessness and
insomnia. There were more skin lesions on the backs especially just above the waist and lower limbs.
These cutaneous manifestations had been shown to be due to the salivary secretions of allergenic
materials by fleas.
There are other possible consequences of this anthropophilic deflection of the dog flea. There are at
least 8 species of fleas that can transmit Pasteurella pestis to man (Lechleitner, 1962) and the number
is increasing. If it is proved that C canis can transmit plague bacillus, then its vectorial importance
becomes immense. It should be noted that Dipeolu and Ayoade, 1981 b, Akinboade et al., 1981
found C. canis on rats (Rattus rattus) in Nigeria and these are regarded as reservoirs of plague bacillus.
In the epidemiology of plague it has been established that fleas from dogs can be a problem as was in
the case of a woman in California, U.S.A. who had been in contact with a dog in a camp-ground.
Also, following an outbreak of plague among Navajo Indians and Prairie dogs (Cynomys gunnisoni) in
Utah, Southern Colorado, Arizona and New Mexico, 48% of domestic dogs tested had significant titres
for P. Pestis antibodies (Schwabe, 1969). Furthermore Adams, Emmons and Brooks (1970) are of the
view that Ctenocephalides sp. may serve as the agent of transfer of Rickttsial infections to man. It
should also be noted that Hymeno/ep/s nana a tapework of man which also occurs in rats has among
its intermediate hosts C. canis.—Fagbemi BO, Ogunji F, Dipeolu OO: Anthropophilic Deflection of
Ctenocephalides canis (Dog Flea). Int] Zoonoses 8: 97, 1981

